Produktname:3-bromo-2-(methoxymethoxy)benzonitrile
IUPAC Name:3-bromo-2-(methoxymethoxy)benzonitrile
- CAS：2065250-66-8
- Molekulare Formel：C9H8BrNO2
- Reinheit：95%+
- Katalognummer：CM1041690
- Molekulargewicht：242.07
| Packungseinheit |
Verfügbarer Vorrat |
Preis($) |
Menge |
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:2065250-66-8
- Molekulare Formel:C9H8BrNO2
- Schmelzpunkt:-
- SMILES-Code:COCOC1=C(C=CC=C1Br)C#N
- Dichte:
- Katalognummer:CM1041690
- Molekulargewicht:242.07
- Siedepunkt:
- Mdl-Nr.:
- Lagerung:
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Paltusotine
- Crinetics’ once-daily oral paltusotine achieved the primary and all secondary endpoints in the phase 3 PATHFNDR-2 study in acromegaly patients.
Acromegaly is a serious rare disease generally caused by a pituitary adenoma, a benign tumor in the pituitary that secretes growth hormone (GH). Excess GH secretion causes excess secretion of IGF-1 from the liver. Prolonged exposure to increased levels of IGF-1 and GH leads to progressive and serious systemic complications, often resulting in bone, joint, cardiovascular, metabolic, cerebrovascular, or respiratory disease.
Paltusotine is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist and is currently in investigational Phase 3 studies for acromegaly and a Phase 2 study for carcinoid syndrome.
Suche 
+86 21 5895 0110 
